Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry
Clemens Muehlan, Hartmut Fischer, Dieter Zimmer, et al.
Current Drug Metabolism (2019) Vol. 20, Iss. 4, pp. 254-265
Closed Access | Times Cited: 23

Showing 23 citing articles:

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Daridorexant: First Approval
Anthony Markham
Drugs (2022) Vol. 82, Iss. 5, pp. 601-607
Open Access | Times Cited: 56
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
Ingo Fietze, Claudio L. Bassetti, David Mayleben, et al.
Drugs & Aging (2022) Vol. 39, Iss. 10, pp. 795-810
Open Access | Times Cited: 32
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem
Mike Ufer, Debra Kelsh, Kerri A. Schoedel, et al.
SLEEP (2021) Vol. 45, Iss. 3
Open Access | Times Cited: 31
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
Clemens Muehlan, Margaux Boehler, Sander Brooks, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 3, pp. 326-335
Closed Access | Times Cited: 29
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Daridorexant in Insomnia Disorder: A Profile of Its Use
Tina Nie, Hannah A. Blair
CNS Drugs (2023) Vol. 37, Iss. 3, pp. 267-274
Open Access | Times Cited: 8
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women
Priska Kaufmann, Clemens Muehlan, Marion Anliker‐Ort, et al.
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 10, pp. 1278-1287
Open Access | Times Cited: 2
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 10, pp. 1349-1360
Closed Access | Times Cited: 17
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis
Uta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 711-721
Closed Access | Times Cited: 17
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist
Martine Géhin, Jolanta Wierdak, Giancarlo Sabattini, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 810-819
Open Access | Times Cited: 16
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects
Clemens Muehlan, Rob Zuiker, Pierre Peeters, et al.
Journal of Clinical Psychopharmacology (2020) Vol. 40, Iss. 2, pp. 157-166
Closed Access | Times Cited: 17
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects
Benjamin Berger, Sander Brooks, Rob Zuiker, et al.
CNS Drugs (2020) Vol. 34, Iss. 12, pp. 1253-1266
Closed Access | Times Cited: 15
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
Benjamin Berger, Clemens Muehlan, Gernot Klein, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 6, pp. 2132-2138
Open Access | Times Cited: 13
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Wojciech Ziemichód, Karolina Grabowska, Antonina Kurowska, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6041-6041
Open Access | Times Cited: 9
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects
Benjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
European Neuropsychopharmacology (2021) Vol. 51, pp. 90-104
Closed Access | Times Cited: 12
Safety and efficacy of daridorexant in the treatment of insomnia: a systematic review and meta-analysis of randomized controlled trials
Muayad Albadrani, Muhannad saud albadrani, Hammad Ali Fadlalmola, et al.
International Clinical Psychopharmacology (2022) Vol. 38, Iss. 1, pp. 57-65
Closed Access | Times Cited: 6
CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4‐Hydroxypiperidinol Metabolites
Alexander Treiber, Hamed Aissaoui, Stéphane Delahaye, et al.
ChemMedChem (2023) Vol. 18, Iss. 10
Closed Access | Times Cited: 3
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
Christine Huynh, Swen Seeland, Jérôme Segrestaa, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 4
A comprehensive review of Dual Orexin Receptor Antagonist (DORA), Daridorexant: Novel drug for sleep and related disorders
Saurav Misra, Manmeet Kaur, Jayant Kumar Kairi
International journal of life sciences, biotechnology and pharma research. (2024) Vol. 13, Iss. 6, pp. 20-29
Open Access
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects
Marion Anliker‐Ort, Jasper Dingemanse, Luboš Janů, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 11, pp. 827-837
Closed Access | Times Cited: 1
The metabolism of the dual orexin receptor antagonist daridorexant
Alexander Treiber, Stéphane Delahaye, Aude Weigel, et al.
Xenobiotica (2023) Vol. 53, Iss. 3, pp. 173-183
Closed Access
Page 1

Scroll to top